ArticleOncology letters2020

Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab.

Valerio Nardone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.